Huons (CEO Um Ki-an), a subsidiary of Huons Global Inc., announced on August 26th that it will participate in the 66th GA2018, International Congress and Annual Meeting of the Society for Medical Plant and Natural Product Research’ held in Shanghai for four days to present the nonclinical results of its ‘Standardized QuisqualisIndica Extract (HU-033)’.
The International Congress and Annual Meeting of the Society for Medical Plant and Natural Product Research is a leading international academic conference held by ‘The Society for Medical Plant Research’, which publishes the world-renowned scientific journal ‘Plata Medica’, will be co-hosted bythe 11th S-TCM, Shanghai International Conference on Traditional Chinese Medicine and Natural Medicines
In this conference, academic presentations were held in 8 fields including natural substances, new drugs and health-related foods. Huons also published the results of a non-clinical study on the mechanism and efficacy of its ‘Standardized QuisqualisIndica Extract (HU-033)’ on prostate hypertrophy and lower urinary tract symptoms.
The HU-033 has proven to have a dual effect on treating prostate hypertrophy and improving urination. The HU-033 is also a natural material derived from oriental medicine and has low potential for toxicity and adverse effects. Furthermore, it has attracted the attention of world medical staffs and researchers who participated in the conference.
The HU-033 has been selected as a government-sponsored agriculture-type industrial technology development project supported by the Ministry of Food, Agriculture, Forestry and Fisheries. Furthermore, it has also been registered for domestic patents and filed patents in nine foreign countries (U.S., Europe, Japan, etc).
Huons is expecting the HU-033 to be commercialized as an orthopedic health functional food and remedy in 2019. In particular, as the disease of urinary system is closely related to ‘quality of life’, Huons will focus on developing healthy food products that focus more on ‘prevention’.
“It is very meaningful to announce nonclinical results on the dual functional effects of treating and urinating prostate hypertrophy in HU-033 at the internationally recognized International Congress and Annual Meeting of the Society for Medical Plant and Natural Product Research. As the nonclinical results alone have drawn great attention from medical staff and researchers attending the conference, there will be a successful application of the HU-033 on a human body in order to open a new era in the global market for improving global health,” said Um Ki-an, CEO of Huons.
